Hexima Limited (ASX:HXL)

📍 Melbourne, Australia🗓 Founded 1998👥 12 employees💰 Last funded Sep 2021
Biotechnology Research🌐 hexima.com.au
Website LinkedIn
Hexima is a clinical stage, anti-infectives focused biotechnology company engaged in the research and development of plant defensin peptides for applications as human therapeutics. Our lead product candidate, pezadeftide (formally HXP124) applied in a topical formulation, is a potential new prescription treatment for toenail fungal infections (or onychomycosis). Hexima is currently conducting an Australian phase IIb clinical trial testing pezadeftide for the treatment of onychomycosis. Hexima holds granted, long-life patents protecting pezadeftide in major markets globally.
1
Total investors
0
Early stage
0
Mid stage
0
Late stage
1998
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Hexima Limited (ASX:HXL)?
Hexima Limited (ASX:HXL) has 1 investors on record on gritt.io.
When did Hexima Limited (ASX:HXL) last raise funding?
The most recent investment in Hexima Limited (ASX:HXL) recorded on gritt.io was in September 2021.
When was Hexima Limited (ASX:HXL) founded?
Hexima Limited (ASX:HXL) was founded in 1998.
What industry is Hexima Limited (ASX:HXL) in?
Hexima Limited (ASX:HXL) operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Hexima Limited (ASX:HXL) based?
Hexima Limited (ASX:HXL) is headquartered in Melbourne, Australia.